Moribund day on Monday, but a green finish
James Dunn
December 12, 2023
The benchmark S&P/ASX 200 (INDEXASX: XJO) index ending the session
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The benchmark S&P/ASX 200 (INDEXASX: XJO) index ending the session
The CSL Limited (ASX:CSL) share price is down around 5.0%
This week, Rask’s Chief Investment Officer, Owen Rask, Wattle Partners
The Resmed CDI (ASX:RMD) share price is down around 18.9%
The Australian market retreated on Thursday, but in a barely
The CSL Limited (ASX:CSL) share price has decreased 5.6% since
The benchmark S&P/ASX 200 (INDEXASX: XJO) index jumped 116.8 points,
Here’s today’s latest updates on the S&P/ASX 200 (INDEXASX: XJO)
The benchmark S&P/ASX 200 (INDEXASX: XJO) index adding 51.5 points,
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
